Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study
- Conditions
- SurgeryMelanoma
- Interventions
- Procedure: Blood samples
- Registration Number
- NCT05817149
- Lead Sponsor
- Aalborg University Hospital
- Brief Summary
We want to test if an association between sentinel lymph node biopsy (SLBN) and a systemic inflammatory response can be made.
- Detailed Description
Sentinel lymph node biopsy (SLBN) is essential in staging melanoma and properly selecting patients for adjuvant immunotherapy. However, surgically induced inflammation can potentially aid in progression of remaining malignant cells and affect prognosis. The inflammatory marker neutrophil-to-lymphocyte ratio (NLR) is also a negative prognostic and predictive marker in serval malignancies, among melanoma. However, it is not yet established if SLNB induces a systemic inflammatory response.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Adult (>18 years of age)
- Diagnosed with invasive cutaneous melanoma
- Eligible for SLNB (Melanoma stage ≥ T1b)
- Obtained signed informed consent
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with melanoma Blood samples Patients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.
- Primary Outcome Measures
Name Time Method Neutrophil-to-lymphocyte ratio 1 Day Ratio between neutrophil granulocytes and lymphocytes
- Secondary Outcome Measures
Name Time Method Pro-inflammatory cytokines 1 Day IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNF-α, and IFN-γ
Acute phase reactants 1 Day CRP, LDH
Trial Locations
- Locations (1)
Aalborg University Hospital
🇩🇰Aalborg, The North Denmark Region, Denmark